Area of research
Nephrology · Surgery
Research interest
Research interests include Medicine, Hypoparathyroidism, Internal medicine, Endocrinology, Parathyroid hormone, and Bone mineral.
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial
Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial
Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial
OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study
Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes
A Pilot Study of Cognition Among Hypoparathyroid Adults
Efficacy and safety with TransCon PTH for adults with hypoparathyroidism through week 84 in the PaTH Forward trial
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
Week 26 results from the PaTH Forward Open-Label Extension Trial Support TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism
Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial
Management of Hypoparathyroidism
Lipocalin-2 is an anorexigenic signal in primates
Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1–84) Therapy in Hypoparathyroidism
Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey
SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety
Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy
PTH and bone material strength in hypoparathyroidism as measured by impact microindentation
Mechanisms of Fracture: Matrix Properties and Cortical Porosity
MC4R-dependent suppression of appetite by bone-derived lipocalin 2
Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism